China is striving to become the global leader in biopharmaceuticals, but many of its policy steps are “innovation mercantilist” in nature. This not only is expected to threaten U.S. leadership, but also slow global life sciences innovation, with negative consequences for cures and treatments.
April 23, 2020
ITIF and the Bayh-Dole 40 Coalition hosted a video webinar delving into the critical role that partnerships between industry, academia, and federal labs will play in combating COVID-19, how these partnerships work, what risks they entail, why patents and licenses are so important in overcoming the risks inherent in developing drugs and vaccines, and how the Bayh-Dole Act enables the process for the benefit of people in the United States and around the world.
April 18, 2020
With two-thirds of the world in lockdown and no clear way out of the novel coronavirus crisis, it’s increasingly obvious that biopharmaceutical innovation will play a pivotal role.
April 3, 2020
As the urgency of finding a treatment and vaccine for the coronavirus accelerates, dozens of American biomedical companies, startups and universities are rushing to develop COVID-19 therapeutics. There’s a good chance the Bayh-Dole Act will play a critical behind-the-scenes role in facilitating these efforts.
March 30, 2020
Dozens of American drug companies and universities are rushing to create COVID-19 therapeutics—and they are better positioned to succeed than their counterparts anywhere else in the world.
February 6, 2020
Stephen Ezell presented about intellectual property’s impact on global health and life-sciences innovation at a Georgetown University course on Globalization and Public Health.
February 5, 2020
Severing the Link Between IP and Biomedical Innovation Isn’t the Answer to Global Health Care Challenges
Delinking the cost of R&D from the final prices of medicines and making governments the funders and planners of drug development would be rife with problems.
February 3, 2020
Separating the cost of biopharmaceutical research and development from the final market price of medicines would misalign incentives, raise bureaucratic costs, and limit innovation.
November 26, 2019
Congress should ratify the proposed USMCA and in particular support its provision requiring 10 years of data protection for biologic drugs. The result will be a more competitive U.S. biopharmaceutical industry, more high-paying American jobs and more incentives to produce new cures.
November 25, 2019
Fact of the Week: A 40 Percent Reduction in U.S. Drug Prices Would Lead to as Much as 60 Percent Fewer Novel Compounds Reaching Clinical Testing
Proponents of capping drug prices often dismiss concerns about the impact on pharmaceutical R&D by pointing to the fact that drug prices are much lower internationally than in the United States. But this reasoning fails to consider that price restrictions in other countries have made pharmaceutical companies disproportionately reliant on revenue from the United States.
October 21, 2019
Fact of the Week: Artificial Price Controls Could Lower the Number of new Drugs by 3 to 5 Percent Over the Next Decade
In response to increased public pressure, both Congress and the Trump Administration have recently promoted efforts to reduce the price of prescription drugs in the United States. Several other countries have already imposed measures of their own.